Izmir Bozyaka Training and Research Hospital, Department of Internal Medicine, Izmir, Turkey.
Gynecol Endocrinol. 2011 Feb;27(2):91-5. doi: 10.3109/09513590.2010.491164. Epub 2010 Jun 8.
To evaluate sCD40L levels in women with polycystic ovary syndrome (PCOS) who use combination therapy with metformin and oral contraceptives.
Total of 60 patients with PCOS was studied to evaluate and compare with a non-PCOS group consisting of 30 subjects. A low-dose oral contraceptive containing ethinyl oestradiol-cyproterone acetate (EE/CA) and metformin (M; 850 mg metformin twice a day) were given for three cycles. Plasma sCD40L was measured before and after the treatment of 3 months.
At baseline, the sCD40L levels of the patients with PCOS was significantly higher than those of control subjects (3.1 ± 2.0 vs. 2.05 ± 1.0, respectively; p=0.002). An average of 3 months of EE/CA-M therapy induced a significant decrease of sCD40L levels in the PCOS group (3.1 ± 2.0 vs. 2.5 ± 1.0; p=0.026). After having treated patients with PCOS, the sCD40L level was not completely normalised when compared to the healthy controls (2.5 ± 1.0 vs. 2.05 ± 1.0; p=0.039).
PCOS is associated with elevated levels of sCD40L. Adding metformin therapy to EE/CA may decrease sCD40L levels in women PCOS. However, after the treatment for PCOS subjects, the sCD40L was not completely normalised when compared patients to healthy controls.
评估多囊卵巢综合征（PCOS）妇女使用二甲双胍和口服避孕药联合治疗时 sCD40L 的水平。
共研究了 60 例 PCOS 患者，并与 30 例非 PCOS 组进行了比较。给予低剂量含炔雌醇环丙孕酮（EE/CA）和二甲双胍（M；每天 850mg 二甲双胍两次）的口服避孕药，治疗 3 个周期。在治疗前和治疗 3 个月后测量血浆 sCD40L。
在基线时，PCOS 患者的 sCD40L 水平明显高于对照组（分别为 3.1±2.0 与 2.05±1.0；p=0.002）。EE/CA-M 治疗平均 3 个月可显著降低 PCOS 组的 sCD40L 水平（3.1±2.0 与 2.5±1.0；p=0.026）。与健康对照组相比，治疗 PCOS 患者后 sCD40L 水平未完全正常化（2.5±1.0 与 2.05±1.0；p=0.039）。
PCOS 与 sCD40L 水平升高有关。在 EE/CA 中添加二甲双胍治疗可能会降低 PCOS 妇女的 sCD40L 水平。然而，与健康对照组相比，在治疗 PCOS 患者后，sCD40L 并未完全正常化。
